Carmel Valley-based MEI Pharma appointed Nick Glover, Ph.D., to its board of directors. The company, focused on clinical development of cancer therapies, announced the appointment of Dr. Glover on Tuesday.
Glover was most recently president and CEO of YM BioSciences, an oncology drug development company acquired by Gilead Sciences for $510 million in February 2013.
“Dr. Glover is a natural fit to round out our Board of Directors, adding a wealth of relevant strategic and operational knowledge,” said Daniel P. Gold, Ph.D., president and CEO of MEI Pharma in an announcement. “In addition to firsthand experience leading an emerging hematology drug development company, Nick has an extensive background in business development and strong relationships within the life science investment community. We look forward to the benefit of his experience as we execute multiple Phase II clinical trials of Pracinostat in the months ahead and formulate strategies for maximizing its value.”
Find out what's happening in Del Mar-Carmel Valleyfor free with the latest updates from Patch.
Pracinostat is the MEI Pharma’s lead drug candidate being developed for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
